Please wait while the formulary information is being retrieved.
MYALEPT (METRELEPTIN)
- Generalized lipodystrophy
5 mg/mL (final concentration) subcutaneous solution
- Inject 1 milliliter (5 mg) by subcutaneous route once daily (same time each day) in the abdomen, thigh,or upper arm rotating injection sites
Generalized lipodystrophy
- Inject 1 milliliter (5 mg) by subcutaneous route once daily at the same time each day in the abdomen, thighs, upper outer areas of buttocks, or outer area of upper arms rotating injection sites
- Inject 1 milliliter (5 mg) by subcutaneous route once daily (same time each day) in the abdomen, thigh,or upper arm rotating injection sites
- Inject 2 milliliters (10 mg) by subcutaneous route once daily at the same time each day in the abdomen, thighs, upper outer areas of buttocks, or outer area of upper arms rotating injection sites
- Inject 0.5 milliliter (2.5 mg) by subcutaneous route once daily at the same time each day in the abdomen, thighs, upper outer areas of buttocks, or outer area of upper arms rotating injection sites
- None
Contraindicated
- None
Severe
Moderate
- None
- Obesity
Contraindicated
- Malignant lymphoma
- Myelodysplastic syndrome
- Neutropenic disorder
- Pancreatitis
Severe
Moderate
- Autoimmune disease
- Diabetes mellitus
- Hypoglycemic disorder
MYALEPT (METRELEPTIN)
- Generalized lipodystrophy
- None
- Acute abdominal pain
- Headache disorder
- Hypoglycemic disorder
- Weight loss
More Frequent
Severe
Less Severe
- None
- Anemia
- Arthralgias
- Back pain
- Diarrhea
- Dizziness
- Fatigue
- Fever
- Infection of ear
- Nausea
- Paresthesia
- Proteinuria
- Upper respiratory infection
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Autoimmune hepatitis
- Glomerulonephritis
- Malignant lymphoma
- Ovarian cyst
- Pancreatitis
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Metreleptin
- Severity Level:
C
- Additional Notes: Consider tx benefit vs risk; prolonged gestation & dystocia seen in mice studies
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Metreleptin
Insuf human data; potential for infant adverse outcomes based on pharmacology
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insuf human data; potential for infant adverse outcomes based on pharmacology |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Generalized lipodystrophy | |
| E88.1 | Lipodystrophy, not elsewhere classified |
| 0-9 | A-Z |
|---|---|
| E88.1 | Lipodystrophy, not elsewhere classified |
Formulary Reference Tool